Stock of the Day

August 19, 2022

Summit Therapeutics (SMMT)

$13.62
-$0.11 (-0.8%)
Market Cap: $10.95B

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Today's Trend

Summit Therapeutics PLC (NASDAQ: SMMT) is gaining investor attention after partner Akeso reported encouraging Phase III results for ivonescimab in biliary tract cancer. The data strengthen the case that Summit’s lead drug could expand beyond non-small cell lung cancer (NSCLC), although execution, regulatory and funding risks remain significant.

  • Positive Phase III biliary tract cancer results: In the HARMONi-GI1 study, ivonescimab delivered an overall-survival benefit and outperformed AstraZeneca’s Imfinzi in Chinese biliary tract cancer patients. The result broadens the drug’s potential market and is the primary catalyst behind recent strength in SMMT shares. SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
  • Pipeline validation: The HARMONi-GI1 findings add to earlier positive ivonescimab data in NSCLC and support Summit’s strategy of developing the Akeso-partnered therapy across multiple cancer indications. The Phase III HARMONi results were also published in The Lancet Oncology, providing additional visibility and credibility. Ivonescimab beats Imfinzi in Chinese biliary tract cancer trial Summit Therapeutics Published Phase III HARMONi Results In The Lancet Oncology
  • More favorable analyst view: A Seeking Alpha analysis upgraded Summit to Buy, citing improving sentiment and upcoming global clinical and regulatory catalysts, including pivotal data and potential FDA decisions. Summit Therapeutics: Signals Of Moving Past Lung Cancer
  • Mixed analyst signals: HC Wainwright reaffirmed its Neutral rating, indicating that the promising clinical data have not yet eliminated uncertainty around commercialization, regulatory approval and valuation.
  • Cash-burn and execution concerns: Summit remains loss-making, and its substantial operating expenses and aggressive pipeline expansion could leave liquidity covering only several quarters. Investors may therefore remain cautious until additional global trial and regulatory milestones are achieved. Summit Therapeutics: Signals Of Moving Past Lung Cancer
← Previous Stock of the DayNext Stock of the Day →

Recent News